Astute Medical, Inc., a San Diego, CA-based developer of novel, biomarker-based medical diagnostics, has completed a $40.4m Series C financing.
The round was led by MPM Capital, with participation from new investor Kaiser Permanente Ventures and existing stockholders De Novo Ventures, Delphi Ventures, Domain Associates and Johnson & Johnson Development Corporation.
The company intends to use the capital to begin commercializing its first product, as well as to advance and expand its research, development and validation of biomarker-based laboratory tests.
Led by CEO Christopher Hibberd, Astute Medical focuses on community and hospital acquired acute conditions that require rapid diagnosis and risk assessment. Its current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis.